During the last session, Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares were 0.73 million, with the beta value of the company hitting 2.48. At the end of the trading day, the stock’s price was $2.56, reflecting an intraday gain of 2.40% or $0.06. The 52-week high for the BDTX share is $7.66, that puts it down -199.22 from that peak though still a striking 9.77% gain since the share price plummeted to a 52-week low of $2.31. The company’s market capitalization is $144.86M, and the average intraday trading volume over the past 10 days was 0.47 million shares, and the average trade volume was 1.18 million shares over the past three months.
Black Diamond Therapeutics Inc (BDTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.14. BDTX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.31.
Black Diamond Therapeutics Inc (NASDAQ:BDTX) trade information
Black Diamond Therapeutics Inc (BDTX) registered a 2.40% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.40% in intraday trading to $2.56, hitting a weekly high. The stock’s 5-day price performance is 6.22%, and it has moved by -18.21% in 30 days. Based on these gigs, the overall price performance for the year is -2.29%. The short interest in Black Diamond Therapeutics Inc (NASDAQ:BDTX) is 6.13 million shares and it means that shorts have 11.67 day(s) to cover.
The consensus price target of analysts on Wall Street is $20, which implies an increase of 87.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20 and $20 respectively. As a result, BDTX is trading at a discount of -681.25% off the target high and -681.25% off the low.
Black Diamond Therapeutics Inc (BDTX) estimates and forecasts
Statistics show that Black Diamond Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Black Diamond Therapeutics Inc (BDTX) shares have gone down -57.12% during the last six months, with a year-to-date growth rate more than the industry average at 30.85% against 17.10.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -49.79%. While earnings are projected to return 30.85% in 2024.
BDTX Dividends
Black Diamond Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s Major holders
Black Diamond Therapeutics Inc insiders own 2.26% of total outstanding shares while institutional holders control 98.75%, with the float percentage being 101.03%. T. ROWE PRICE INVESTMENT MANAGEMENT, INC. is the largest shareholder of the company, while 130.0 institutions own stock in it. As of 2024-06-30, the company held over 10.66 million shares (or 20.5751% of all shares), a total value of $49.67 million in shares.
The next largest institutional holding, with 8.52 million shares, is of BELLEVUE GROUP AG’s that is approximately 16.4409% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $39.69 million.
